Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist

1. A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, wherein the pre-filled pharmaceutical package comprises:

a wall comprising a cyclic olefin polymer, having an interior surface enclosing at least a portion of a lumen;

a tie coating or layer on the wall interior surface comprising SiO x C y H z , in which x is from about 0.5 to about 2.4 as measured by X-ray photoelectron spectroscopy (XPS), y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of Rutherford backscattering spectrometry (RBS) or hydrogen forward scattering (HFS);

a barrier coating or layer of SiO x , in which x is from about 1.5 to about 2.9 as measured by XPS, the barrier coating or layer positioned between the tie coating or layer and the lumen;

a pH protective coating or layer of SiO x C y H z , in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS, positioned between the barrier coating or layer and the lumen;

a lubricity coating or layer positioned between the pH protective coating or layer and the lumen, wherein the lubricity coating or layer has the atomic proportions SiOxCyHz, in which x is from about 0.5 to about 2.4 as measured by XPS, y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by at least one of RBS or HFS;

a liquid formulation of a VEGF-antagonist in the lumen; and

a closure closing the lumen;

wherein the VEGF antagonist is Ranibizumab.

2. The prefilled pharmaceutical package according to claim 1 , in which the liquid formulation of Ranibizumab in the lumen comprises Ranibizumab at a concentration of 6 or 10 mg/ml.

3. The pre-filled pharmaceutical package according to claim 1 , having a nominal maximum fill volume of 0.5 or 1 mL.

4. The pre-filled pharmaceutical package according to claim 1 , in which the liquid formulation of Ranibizumab contains no more than 50 particles ≥10 μm diameter per mL, no more than 5 particles ≥25 μm diameter per mL, and/or no more than 2 particles ≥50 μm diameter per mL, during shelf life, measured by microscopic inspection.

5. The pre-filled pharmaceutical package according to claim 1 , which is free of baked-on silicone.

6. The pre-filled pharmaceutical package according to claim 1 , which is terminally sterilized.

7. The pre-filled pharmaceutical package according to claim 1 , in which the liquid formulation of Ranibizumab in the lumen forms an equal or smaller area % of basic decomposition species, after storage of the pharmaceutical package at 5° C. for three months, than a glass pharmaceutical package of the same volumetric capacity, internally coated with baked-on silicone.

8. The pre-filled pharmaceutical package according to claim 1 , in which the liquid formulation of Ranibizumab in the lumen forms an equal or smaller area % of acidic decomposition species, after storage of the pharmaceutical package at 5° C. for three months, than a glass pharmaceutical package of the same volumetric capacity, internally coated with baked-on silicone.

9. The pre-filled pharmaceutical package according to claim 1 , in which the Ranibizumab retains its biological activity when stored at a temperature of 2 to 8° C. for at least six months.

10. The pre-filled pharmaceutical package according to claim 1 , being a syringe.

11. The pre-filled pharmaceutical package according to claim 10 , comprising a plunger which comprises a side surface slidable along the wall, wherein at least a portion of the side surface comprises a fluoropolymer lubricity coating or layer abutting the wall.

12. The pre-filled pharmaceutical package according to claim 10 , having a breakout force less than or equal to 15N for initiating travel of the stopper in the lumen.

13. The pre-filled pharmaceutical package according to claim 10 , having a plunger sliding force less than or equal to 15N for advancing the stopper in the lumen.

14. The pre-filled pharmaceutical package of claim 1 for use in administering a liquid formulation of a VEGF-antagonist to a patient having an ocular disease.

15. The pre-filled pharmaceutical package for the use according to claim 14 , wherein the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME), visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), or visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia.

16. The pre-filled pharmaceutical package for the use according to claim 14 , wherein the VEGF antagonist is Ranibizumab which is administered in a volume of 0.05 mL.

17. A liquid formulation of a VEGF-antagonist in a pre-filled pharmaceutical package according to claim 1 , in which the liquid formulation of Ranibizumab has been adjusted to pH 5.5 with HCl.

18. A liquid formulation of a VEGF-antagonist in a pre-filled pharmaceutical package according to claim 1 , in which the liquid formulation of Ranibizumab in the lumen comprises, per mL of formulation:

6 or 10 mg. Ranibizumab;

100 mg. α,α-trehalose dihydrate;

0.32 mg. L-histidine

1.66 mg. L-histidine hydrochloride monohydrate;

0.1 mg Polysorbate 20; and

water for injection qs to 1 mL.

19. Kit comprising one or more pre-filled pharmaceutical packages according to claim 1 .